ArticleNature medicine2019
Enhancer signatures stratify and predict outcomes of non-functional pancreatic neuroendocrine tumors.
Erratum issuedAbstract read
In one paragraph
Article in Nature medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 105 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 2 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
105 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Metabolism of pancreatic neuroendocrine tumors: what can omics tell us?Frontiers in endocrinology · 2023Pooled it
- Prognostic factors for the outcome of nonfunctioning pancreatic neuroendocrine tumors in MEN1: a systematic review of literature.Endocrine-related cancer · 2020Pooled it
- Expanded GEP-NET organoid culture for personalized therapy evaluation.Science advances · 2026Article
- Single-Cell and Spatial Transcriptomics Reframe the Immunosuppressive Microenvironment of Neuroendocrine Neoplasms.Cancers · 2026Review
- Distinct Malignant Cell States and Myeloid Glutamate Signaling Associated with Aggressive Pancreatic Neuroendocrine Tumors.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Serotonin Expression and β-Cell Phenotype Are Associated With Indolent Behavior in Pancreatic Neuroendocrine Tumors With Sclerosing Morphology.Journal of surgical oncology · 2026Article
- Clinicopathological and molecular determinants of pancreatic neuroendocrine tumors: toward precision risk stratification.Journal of translational medicine · 2026Review
- Calcium Channel Blockers Inhibit Pancreatic Neuroendocrine Neoplasms Progression via Cav1.2-Epigenetic Circuit.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Molecular taxonomy of pancreatic neuroendocrine tumors reveals BEND2-fusions-driven transcriptional plasticity and therapeutic vulnerabilities.Cell reports. Medicine · 2026Article
- Novel concepts of cell-of origin in neuroendocrine neoplasms.Virchows Archiv : an international journal of pathology · 2026Review
- Epigenetic subtypes of high-grade T1 bladder cancer reveal intra-tumor heterogeneity and distinct interactions with tumor microenvironment.Theranostics · 2026Article
- Concept of neuroendocrine neoplasms of all organs with a focus on grading, subtyping.Virchows Archiv : an international journal of pathology · 2026Review
- Expression of ATRX, DAXX, PDX1, ARX, and somatostatin receptors in pancreatic neuroendocrine tumors: a clinicopathological study.Frontiers in endocrinology · 2026Article
- Recent advances and treatment strategies in liver metastasis of pancreatic neuroendocrine tumors.Cancer metastasis reviews · 2025Review
- Review
- Recurrent BEND2 Fusion Genes Identified by Whole Transcriptome Sequencing of Nonfunctional Pancreatic Neuroendocrine Tumors Correlate With Poor Patient Prognosis.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Decoding Pancreatic Neuroendocrine Tumors: Molecular Profiles, Biomarkers, and Pathways to Personalized Therapy.International journal of molecular sciences · 2025Review
- Myc family proteins: Molecular drivers of tumorigenesis and resistance in neuroendocrine tumors.Biochimica et biophysica acta. Reviews on cancer · 2025Review
- Management of patients with small pancreatic neuroendocrine tumors from a biomarker and surgical perspective.Endocrine-related cancer · 2025Review
- Deep sequencing reveals distinct microRNA-mRNA signatures that differentiate pancreatic neuroendocrine tumor from non-diseased pancreas tissue.BMC cancer · 2025Article
45 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issued
Authors and funding
27 authors.
Paloma Cejas *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Yotam Drier *Broad Institute of Harvard and MIT, Cambridge, MA, USA. yotam.drier@mail.huji.ac.il.ORCID http://orcid.org/0000-0003-1725-2995
Koen M A DreijerinkDepartment of Endocrine Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Lodewijk A A BrosensDepartment of Pathology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Vikram DeshpandeDepartment of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Charles B EpsteinBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0001-8358-8345
Elfi B ConemansDepartment of Endocrine Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Folkert H M MorsinkDepartment of Pathology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Mindy K GrahamDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
Gerlof D ValkDepartment of Endocrine Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Menno R VriensDepartment of Surgical Oncology, UMC Utrecht Cancer Center, Utrecht, the Netherlands.
Carlos Fernandez-Del CastilloDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Cristina R FerroneDepartment of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Tomer AdarDepartment of Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Michaela BowdenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Holly J WhittonBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Annacarolina Da SilvaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Alba Font-TelloCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Henry W LongCenter for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA, USA.
Elizabeth GaskellBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Noam ShoreshBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Christopher M HeaphyDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0003-4264-1810
Ewa SicinskaDepartment of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA, USA.
Matthew H KulkeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Daniel C ChungDepartment of Gastroenterology Division, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Bradley E BernsteinBroad Institute of Harvard and MIT, Cambridge, MA, USA. bernstein.bradley@mgh.harvard.edu.ORCID http://orcid.org/0000-0002-5726-6278
Ramesh A ShivdasaniDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. ramesh_shivdasani@dfci.harvard.edu.ORCID http://orcid.org/0000-0002-2828-1727
Funding
Tissue and Pathology ResourcesP50CA127003 · NCI · DANA-FARBER CANCER INST · PI EL-BARDEESY, NABEEL, SELLERS, WILLIAM R · 2007 to 2023
$33.2MEstablishing in vitro carcinoma models of the Alternative Lengthening of Telomeres pathway to elucidate molecular mechanisms and identify therapeutic vulnerabilitiesF32CA213742 · NCI · JOHNS HOPKINS UNIVERSITY · PI GRAHAM, MINDY KIM · 2017 to 2018
$118kNCI NIH HHS F32 CA213742NCI NIH HHS P50 CA127003
Abstract
Most pancreatic neuroendocrine tumors (PNETs) do not produce excess hormones and are therefore considered 'non-functional'
Indexed as
Enhancer Elements, GeneticCell LineageHomeodomain ProteinsHumansMutationPancreatic NeoplasmsProto-Oncogene ProteinsTelomereTrans-ActivatorsTranscription FactorsARX protein, humanHomeodomain ProteinsMEN1 protein, humanpancreatic and duodenal homeobox 1 proteinProto-Oncogene ProteinsTrans-ActivatorsTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.